Scientific data about the efficacy and safety of fecal microbiota transplantation (FMT) for adult and pediatric patients with recurring or resistant Clostridioides difficile were among the topics covered a recent FDA hearing on the topic.
The FDA is trying to balance the scientific development and approval of a commercial product and open-label access, via stool banks, for patients who need a treatment immediately—before a commercial product is available.